Suchergebnisse - "Berliba, Elina"

PubPharm (7)

1

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B

enthalten in: Hepatology communications | 2022

von Yuen, M. | Berliba, E. | Sukeepaisarnjaroen, W. | +17

2

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Gane, E. | Schwabe, C. | Berliba, E. | +12

3

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2022

von Sandborn, W. | Ferrante, M. | Bhandari, B. | +11

4

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B

enthalten in: Hepatology communications | 2022

von Yuen, M. | Berliba, E. | Sukeepaisarnjaroen, W. | +17

5

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

enthalten in: Gastroenterology | 2020

von Sandborn, W. | Ferrante, M. | Bhandari, B. | +11

CommentIn: Gastroenterology. 2020 Feb;158(3):467-470. - PMID 31862200

6

Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis

enthalten in: Antimicrobial agents and chemotherapy | 2019

von Berliba, E. | Bogus, M. | Vanhoutte, F. | +7

7

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

enthalten in: PloS one | 2018

von McClure, M. | Berliba, E. | Tsertsvadze, T. | +13

1
[1]